Plain-English translation of NCT07142954 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Alzheimer Disease research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
The ANCHOR-AD study is tracking about 3,400 people who currently have no memory problems to understand how a brain protein called P-tau217 changes over time. Researchers will test your blood once a year to measure this protein and follow your thinking and memory through the study. This is not testing a medication — it's a research effort to learn whether this blood test could help predict who might develop Alzheimer's disease in the future.
Doctors want to find early warning signs that someone may develop Alzheimer's disease before memory problems actually start. By measuring this brain protein in blood, researchers hope to identify people at higher risk so that treatments or interventions could potentially help them later.
You likely qualify if…
You likely don't qualify if…
Each year, you will have your blood drawn to measure the brain protein level. The study team will also ask you about your memory and thinking through questionnaires and tests. You'll be followed over time to see how the protein changes and whether any changes relate to your memory and thinking ability. There is no medication to take — the main commitment is returning for your annual blood test and completing thinking assessments.
AI-generated summary from trial data · Jul 10, 2026 · Not medical advice
United States
Japan